SYSTEM FOR DELIVERING NEBULIZED CYCLOSPORINE AND METHODS OF TREATMENT

• US 20100163021A1
• Filed: 02/22/2007
• Published: 07/01/2010
• Est. Priority Date: 02/22/2006
• Status: Abandoned Application

• Current Assignee: Novartis Ag
• Original Assignee: Novartis Pharma AG (Novartis Ag)
• Inventors: Lai, Johnny
• Application Number:
  US12/280,120
• Publication Number:
  US 20100163021A1
• Time in Patent Office: Days
• US Class Current: 128/200.230
• CPC Class Codes: A61M 16/0093 by adsorption, absorption or filtration
• CPC Class Codes: A61M 16/105 Filters A61M16/047, A61M16/22 take precedence; water traps A61M16/08
• CPC Class Codes: A61M 16/1065 in the expiratory path
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 37/06 Immunosuppressants, e.g. drugs for graft rejection

Abstract

Systems comprising a pressurized delivery device and a formulation of cyclosporine coupled to an exhalation filter or trap that is capable of preventing cyclosporine from escaping into the local environment are provided. An apparatus for use in the system comprises either an exhalation filter and a pressurized delivery device, wherein the exhalation filter is capable of providing high filter efficiency and maintaining low filter resistance after usage with the formulation, or a trap which provides a means for expired gas to be released into a solvent chamber containing a solvent with a high affinity for cyclosporine. These systems may be used to treat patients with pulmonary disorders, organ transplant patients such as lung transplant patients, and other immune-related disorders.

Claims

1. An apparatus for administration of aerosolized cyclosporine, comprising,

a pressurized delivery device coupled to an exhalation filter or trap, wherein the exhalation filter or trap is capable of maintaining an efficiency of greater than 90% during usage with a liquid formulation comprising cyclosporine for aerosolization by the device.

2. The apparatus according to claim 1, wherein said exhalation filter is capable of maintaining an increase in filter resistance between a new filter and after usage of the formulation of less than 0.1 cmH₂O^0.5·

min/L.

3. The apparatus according to claim 2, wherein the exhalation filter is a hydrophobic high efficiency particulate air (HEPA) filter.

4. The apparatus according to claim 3, wherein the HEPA filter comprises a polypropylene and/or acrylic medium.

5. The apparatus according to claim 3, wherein the exhalation filter is an Isogard HEPA Light filter.

6. The apparatus according to claim 1, wherein said trap comprises a solvent with a high affinity for cyclosporine.

7. The apparatus according to claim 6, wherein said solvent trap captures escaping cyclosporine particles.

8. A system comprising the apparatus of claim 1 and a liquid formulation comprising cyclosporine for aerosolization by the device.

9. The system according to claim 8, wherein the exhalation filter is a hydrophobic high efficiency particulate air (HEPA) filter.

10. The system according to claim 9, wherein the HEPA filter comprises a polypropylene and/or acrylic medium.

11. The system according to claim 9, wherein the exhalation filter is an Isogard HEPA Light filter.

12. The system according to claim 8, wherein said liquid formulation comprises cyclosporine and a solvent selected from the group consisting of ethanol, propylene glycol, polyethylene glycol, ethanol-propylene combinations, phospholipids, lipids, tetrahydrofurfuryl alcohol, polyethyleneglycol ether and glycerin.

13. The system according to claim 8, wherein said liquid formulation comprises cyclosporine and propylene glycol.

14. The system according to claim 8, wherein said liquid formulation comprises cyclosporine and ethanol.

15. The system according to claim 8, wherein the pressurized delivery device is a nebulizer and the formulation is present in an amount less than 10 mL.

16. The system according to claim 15, wherein the formulation is present in an amount less than 7 mL.

17. The system according to claim 15, wherein the formulation is present in an amount less than 5 mL.

18. The system according to claim 15, wherein the formulation is present in an amount less than 3 mL.

19. The system according to claim 15, wherein the formulation is present in an amount less than 2 mL.

20. The system according to claim 12, wherein the formulation contains 62.5 mg/ml of cyclosporine A.

21. The system according to claim 16, wherein the formulation contains 325 mg cyclosporine and 5.2 ml propylene glycol.

22. A method of treating a pulmonary disorder comprising:

administering aerosolized cyclosporine using the system according to claim 6, to a lung of a subject having a pulmonary disorder.

23. The method according to claim 22, wherein the pulmonary disorder is cystic fibrosis.

24. The method according to claim 22, wherein the lung is a transplanted lung.

25. A method of preventing graft rejection in an organ transplant patient comprising administering to a subject an effective dose of aerosolized cyclosporine using the system according to claim 8.

26. The method according to claim 25, wherein the organ is a lung.

27. The method as according to claim 26, wherein the formulation is administered directly after lung transplantation.

28. A method for selecting an exhalation filter for use in a system comprising a nebulizer coupled to the exhalation filter, wherein the nebulizer contains a liquid formulation comprising cyclosporine, comprising:

turning on a compressor and a respirator pump in a breathing apparatus to nebulize the solution, wherein the apparatus comprises a test exhalation filter, the compressor, the respirator pump, an inhalation filter, a trap filter, and a nebulizer containing said liquid cyclosporine formulation wherein the components of the apparatus are coupled to each other to form the breathing apparatus capable of simulating breathing;

turning off the compressor and the respirator pump after the nebulizer runs dry;

measuring the test filter efficiency by testing the trap filter to measure the quantity of cyclosporine that passed through the test filter;

measuring the filter resistance of the test filter, wherein a filter efficiency of greater than 90%, and an increase in filter resistance between the test filter before the turning on step and after the turning off step of less than 0.1 cmH₂O^0.5·

min/L, are indicative of an appropriate exhalation filter to be used with said solution.